A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rak wątroby (badaniem histologicznym lub kliniczne kryteria dla pacjentów z marskością)
- •Co najmniej jeden niezleczony guz, który można zmierzyć
- •Zaawansowana, rozprzestrzeniona lub niemożliwa do wycięcia choroba
- •Brak wcześniejszego leczenia systemowego zaawansowanego raka wątroby
- •Dobra funkcja wątroby (klasa Child-Pugh A)
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-1)
- •Wyniki badań krwi w normie: liczba neutrofili ≥1500, płytki ≥100000, hemoglobina ≥9.0, bilirubina ≤1.5x norma
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Alabama at Birmingham
Birmingham, United States
Trial contact
Margaret Thomas, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.